Paid Clinical Trials in Centralia, WA
As of September 2026, 30 paid clinical trials are recruiting in Centralia, Washington. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Centralia offers studies at sites including Providence Regional Cancer System-Centralia for conditions such as Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Ovarian Carcinoma, Prostate Adenocarcinoma. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Centralia
Trials by drug in Centralia
Filter results
30 clinical trials
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Family Communications After Genetic Testing
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Adapting a Brief Suicide Intervention for Pediatric Primary Care: Enhancing Uptake and Impact
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Top Research Study Locations in Centralia
Researchers run research studies in Centralia, WA at 2 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Providence Regional Cancer System-Centralia | Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Ovarian Carcinoma | 29 |
| Northwest Pediatrics | Suicide Prevention | 1 |
Active & Upcoming Studies in Centralia (2026)
Recruiting trials in Centralia grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (22 active studies)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations · Phase 3 · SWOG Cancer Research Network
- Family Communications After Genetic Testing · Alliance for Clinical Trials in Oncology
Common conditions studied in Centralia
- Malignant Solid Neoplasm (3 active studies)
- Hematopoietic and Lymphoid Cell Neoplasm (2 active studies)
- Ovarian Carcinoma (2 active studies)
- Prostate Adenocarcinoma (2 active studies)
- Acral Lentiginous Melanoma (1 active study)
- Acute Lymphoblastic Leukemia (1 active study)
Leading research sponsors in Centralia
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
- Canadian Cancer Trials Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Centralia?
There are approximately 30 recruiting clinical trials in Centralia, Washington listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Centralia pay participants?
Most recruiting trials in Centralia compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Centralia?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Centralia?
The most common conditions under active study in Centralia include Malignant Solid Neoplasm (3), Hematopoietic and Lymphoid Cell Neoplasm (2), Ovarian Carcinoma (2), Prostate Adenocarcinoma (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Centralia?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Centralia on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Centralia?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Centralia?
Recruiting research sites in Centralia include Providence Regional Cancer System-Centralia, Northwest Pediatrics, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Centralia right now?
The largest active categories in Centralia are Cancer & tumors (22). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.